Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY trial
<p>Background: In sub-Saharan Africa, 20%-25% of people starting ART have severe immunosuppression; ~10% die within three months. In the recently-reported REALITY randomized trial, a broad enhanced anti-infection prophylaxis bundle reduced all-cause mortality versus cotrimoxazole alone; here,...
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Journal article |
Published: |
Oxford University Press
2018
|